[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY33542A - USE OF TERIFLUNOMIDE TO TREAT MULTIPLE SCLEROSIS - Google Patents

USE OF TERIFLUNOMIDE TO TREAT MULTIPLE SCLEROSIS

Info

Publication number
UY33542A
UY33542A UY0001033542A UY33542A UY33542A UY 33542 A UY33542 A UY 33542A UY 0001033542 A UY0001033542 A UY 0001033542A UY 33542 A UY33542 A UY 33542A UY 33542 A UY33542 A UY 33542A
Authority
UY
Uruguay
Prior art keywords
teriflunomide
multiple sclerosis
treat multiple
treat
treatment
Prior art date
Application number
UY0001033542A
Other languages
Spanish (es)
Inventor
Rocklin Ross
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of UY33542A publication Critical patent/UY33542A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Esta invención se refiere al uso de teriflunomida para el tratamiento de la Esclerosis Múltiple(EM) y para tratar los riesgos asociados con el uso de teriflunomida.This invention relates to the use of teriflunomide for the treatment of Multiple Sclerosis (MS) and to treat the risks associated with the use of teriflunomide.

UY0001033542A 2010-08-02 2011-08-02 USE OF TERIFLUNOMIDE TO TREAT MULTIPLE SCLEROSIS UY33542A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36977910P 2010-08-02 2010-08-02
US36978010P 2010-08-02 2010-08-02
US38937510P 2010-10-04 2010-10-04
US201061424717P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
UY33542A true UY33542A (en) 2012-02-29

Family

ID=45559773

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033542A UY33542A (en) 2010-08-02 2011-08-02 USE OF TERIFLUNOMIDE TO TREAT MULTIPLE SCLEROSIS

Country Status (4)

Country Link
EP (1) EP2600861A1 (en)
AR (1) AR082436A1 (en)
UY (1) UY33542A (en)
WO (1) WO2012018704A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
JOP20190207A1 (en) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd Pharmaceutical combination comprising ponesimod
KR20220166827A (en) * 2020-04-09 2022-12-19 노파르티스 아게 Ofatumumab to treat MS while maintaining serum IgG

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Also Published As

Publication number Publication date
EP2600861A1 (en) 2013-06-12
WO2012018704A1 (en) 2012-02-09
AR082436A1 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
CR20130550A (en) CYCLOPROPILAMINS AS INHIBITORS OF DEMETHYLASE 1 SPECIFIC TO LISINA
ECSP14017269A (en) COMPOUNDS TO TREAT SPINAL MUSCULAR ATROPHY
MX2013015311A (en) Pcsk9-binding polypeptides and methods of use.
ECSP15026557A (en) COMPOUNDS AND THEIR METHODS OF USE
GT201400057A (en) 3-PIRMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF THE MUTANT HDI
CL2012003385A1 (en) Incontinence treatment.
EA201270619A1 (en) USE OF BETANEHOL FOR THE TREATMENT OF XEROSTOMY
CR20130045A (en) THERAPEUTIC COMPOUNDS
ECSP13012786A (en) ANTI-PCSK9 ANTIBODIES AND METHODS OF USE
AR089993A1 (en) PEPTIDOMIMETIC MACROCICLES
CL2013000675A1 (en) Compounds derived from substituted pyrazolamide, with activity on pge2 / ep4; pharmaceutical composition that includes them; and its use for the treatment of multiple sclerosis and rheumatoid arthritis.
UY34037A (en) NEW USEFUL COMPOUND FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES.
RS53893B1 (en) Use of biotin for the treatment of multiple sclerosis
CO6410315A2 (en) NEW ANTI-ALFA5BETA1 ANTIBODIES AND THEIR USES
DOP2014000098A (en) 2-THIOPIRIMIDINONES
IN2014CN04014A (en)
CL2015000976A1 (en) Compounds of 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine for use in the treatment of diabetes and its associated disorders.
UY34616A (en) NEW USEFUL COMPOUND FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES.
UY34315A (en) ? USE OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF HYPOGONADISM AND RELATED DISEASES?
BR112014000634A2 (en) Methods for treating incontinence associated with sexual activity
BR112014009456A2 (en) use of melatonin for the treatment and / or prevention of mucositis
IN2015DN01524A (en)
UY33542A (en) USE OF TERIFLUNOMIDE TO TREAT MULTIPLE SCLEROSIS
CR20130138A (en) PROCESS FOR THE PREPARATION OF PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIARIES OF THE PREPARATION
CR20150159A (en) OXAZOLIDINONA 3,4-DISPOSED DERIVATIVES AND THEIR USE AS INHIBITORS OF POTASSIUM CALCIUM ACTIVATED